Company Overview
Development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost effective, accurate and available to all women regardless of age, race and geographic location.
Website | www.bcaldiagnostics.com |
---|---|
Head Office | Sydney NSW |
Registry | Automic Registry Services |
CEO | John Hurrell |
Chair Person | Jayne Shaw |
GICS Industry | Pharmaceuticals, Biotechnology & Life Sciences |
Sub Industry | Biotechnology |
Sector | Health Care |
Market Cap | $8 m |
---|---|
Shares on Issue | 136 m |
Status | Trading |
Last Price | |
Change | |
52 Week H/L | |
VWAP | |
Bid/Ask |
Directors and Management
Mr Mark Douglas Irving Burrows
Non-Executive Director 21/07/2021
Mr Burrows has experience in diagnosis of breast cancer and other cancers. He has career in investment banking both in Australia and the UK. Mark co-founded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/ Deputy Chairman of ING Barings in London. In 2004, Mark joined Lazard as a Managing Partner and in 2006 returned to Australia and was appointed Lazard Australia's inaugural Chairman. Mark returned to investment banking in 2011 as Vice Chairman of Credit Suisse's Global Investment Bank. During his investment banking career, Mark has been the principal financial advisor to some of the transformative corporate and government transactions in Australia. Mark has served as a non-executive director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra. Since the Rio Earth Summit in 1992, Mark has also been supporter of global financial institutions' Private Sector involvement in sustainable development. Over this period, Mark has retained a number of roles advising United Nations, G20 and corporates on climate initiatives relating to the financial sector. From 2017 to 2020, Mark was a Senior Advisor to Macquarie Bank, on climate finance and renewable energy. Mark currently retains a role as a senior advisor to UNEP, UNDP, The Green Finance Initiative in London and is on the Asian Council of The Nature Conservancy. He is also a Senior Advisor to the G20 Sustainability Group.
AO Male
Ms Jayne Andrea Shaw
Executive Chairman,Executive Director 15/02/2010
Ms Shaw has become a Director of Nursing and Chief Executive Officer of two private hospitals in Australia after completion of her training in nursing. Following this, she established an Australian and international consulting business which was sold to Healthsouth, a USA Healthcare company. Jayne then became the Co-founder of Vision Group, an Ophthalmic Doctor equity consolidation model that was successfully listed on the ASX. Jayne joined a number of private healthcare boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women's Health, and continued to work with private equity firms on local and international healthcare transactions. Jayne, together with Ron Phillips, was a co-owner of Sydney Breast Clinic and a co-founder of BCAL. Current board positions are The Woolcock Research Institute, Corum Group (ASX: COO) and Mable Technologies.
Registered Nurse Female
Dr Merilyn Joy Sleigh
Non-Executive Director 31/03/2021
Dr Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia's biotechnology sector. She was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that expanded internationally and listed on the ASX before acquisition by a larger company. She was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. She has held non-executive director positions with Mimetica Pty Ltd and Adalta Ltd as well as with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd. Other director roles have been with government and not-for-profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia. She has acted as an adviser and consultant to companies, government, research institutes and investors on technology commercialization. She is also member of the Risk Management Committee of BDX.
BSc, PhD, DipCorpMgt,FAICD,FTSE, Female
Mr Jonathan Alfred Grey Trollip
Non-Executive Director 23/12/2020
Mr Trollip is an experienced Director with over 30 years of commercial, corporate, governance and legal and transactional experience. He is currently non-executive Chairman of ASX listed Global Value Fund Limited, Future Generation Investment Company Limited, Antipodes Global Investment Company Limited, Plato Income Maximser Limited, and Spheria Emerging Companies Limited and a non-executive director of ASX listed Propel Funeral Partners Limited and LSE listed Kore Potash PLC. He has experience in the not-for-profit sector. He is also chairman of the Risk Management Committee of BDX.
BA(Eco),PostGrad(Eco & Law), FAICD, LLM, Male
Hon Ronald (Ron) Anthony Phillips
Non-Executive Director 15/02/2010
The Hon Phillips has been worked for 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition. Ron has developed a consulting business in the Health and Aged Care Industry. His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He recently retired as Chair of the Sydney Local Health District and as Director of Westmead IVF. He is also member of the Risk Management Committee of BDX.
AO Male
Top 20 Shareholders
Name | Shares | % | |
---|---|---|---|
1. | Nabelle Pty Ltd (The Shaw Super Fund A/C) | 19,162,405 | 9.26 |
2. | The Trust Company (Australia) Limited (MOF A/C) | 17,420,171 | 8.42 |
3. | Ann Marie Phillips | 16,574,988 | 8.01 |
4. | Mera Vale No 3 Pty Ltd (Mera Vale No 3 A/C) | 12,943,471 | 6.26 |
5. | Ronald Anthony Phillips | 8,102,858 | 3.92 |
6. | Regal Funds Management | 7,971,945 | 3.85 |
7. | Coolbrun Pty Ltd | 6,633,789 | 3.21 |
8. | Nabelle Pty Ltd (The Shaw Family A/C) | 5,815,172 | 2.81 |
9. | Carwoola Pastoral Co Pty Ltd | 4,424,895 | 2.14 |
10. | CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) | 4,000,000 | 1.93 |
11. | Barrijag Pty Ltd (Hadley Family A/C) | 3,890,741 | 1.88 |
12. | Bizcapital Pty Limited | 3,562,205 | 1.72 |
13. | Angelo Korsanos & Antonia Korsanos (Korsanos Family A/C) | 3,484,050 | 1.68 |
14. | Vintage Dawn Pty Ltd (Jamie & Caroline Odell S/F) | 3,484,050 | 1.68 |
15. | Sean Kennedy | 3,300,303 | 1.60 |
16. | Peter French | 3,259,408 | 1.58 |
17. | Piaster Pty Ltd (Trollip Family S/F A/C) | 3,147,649 | 1.52 |
18. | Darville Pty Limited | 3,101,660 | 1.50 |
19. | Scapa Pty Ltd | 3,048,563 | 1.47 |
20. | Peter Alan Murray | 2,819,558 | 1.36 |
21. | UBS Nominees Pty Ltd | 2,725,000 | 1.32 |
Director Transactions
Date | Name | Qty | Value | Direction | Notes |
---|---|---|---|---|---|
07/09/2021 | Jayne Shaw | 20,000 | $4,002 | Buy | On-market trade. |
06/09/2021 | Jayne Shaw | 180,000 | $36,000 | Buy | On-market trade. |